Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
BACKGROUND: Statin intolerance is a medical condition often leading patients to nonadherence to the prescribed therapy or to a relevant reduction of the statin dosage. Both situations determine a totally or partially uncontrolled lipid profile, and these conditions unquestionably increase the risk of cardiovascular events.
METHODS: We enrolled hypercholesterolemic, type 2 diabetic patients complaining of intolerance to statins. Some of them had reduced the statin dose 'until the disappearance of symptoms'; others had opted for treatment with ezetimibe; and yet others were not undergoing any treatment at all. All patients of the three groups were then given a fixed combination of berberine and silymarin (Berberol(®)), known from previous papers to be able to control both lipidic and glycemic profiles.
RESULTS: The tested product both as a single therapy and as add-on therapy to low-dose statin or to ezetimibe reduced triglycerides, low-density lipoprotein cholesterol, fasting blood glucose, and glycosylated hemoglobin in a significant manner without inducing toxicity conditions that might be somehow ascribed to a statin-intolerant condition.
CONCLUSION: Our study demonstrates that use of Berberol(®), administered as a single or add-on therapy in statin-intolerant subjects affected by diabetes and hypercholesterolemia is a safe and effective tool capable of improving the patients' lipidic and glycemic profiles.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Diabetes, metabolic syndrome and obesity : targets and therapy - 8(2015) vom: 01., Seite 89-96 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Pierro, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Berberine |
|---|
| Anmerkungen: |
Date Completed 14.02.2015 Date Revised 30.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/DMSO.S78877 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM246208791 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM246208791 | ||
| 003 | DE-627 | ||
| 005 | 20231224142550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/DMSO.S78877 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0820.xml |
| 035 | |a (DE-627)NLM246208791 | ||
| 035 | |a (NLM)25678808 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Pierro, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2015 | ||
| 500 | |a Date Revised 30.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Statin intolerance is a medical condition often leading patients to nonadherence to the prescribed therapy or to a relevant reduction of the statin dosage. Both situations determine a totally or partially uncontrolled lipid profile, and these conditions unquestionably increase the risk of cardiovascular events | ||
| 520 | |a METHODS: We enrolled hypercholesterolemic, type 2 diabetic patients complaining of intolerance to statins. Some of them had reduced the statin dose 'until the disappearance of symptoms'; others had opted for treatment with ezetimibe; and yet others were not undergoing any treatment at all. All patients of the three groups were then given a fixed combination of berberine and silymarin (Berberol(®)), known from previous papers to be able to control both lipidic and glycemic profiles | ||
| 520 | |a RESULTS: The tested product both as a single therapy and as add-on therapy to low-dose statin or to ezetimibe reduced triglycerides, low-density lipoprotein cholesterol, fasting blood glucose, and glycosylated hemoglobin in a significant manner without inducing toxicity conditions that might be somehow ascribed to a statin-intolerant condition | ||
| 520 | |a CONCLUSION: Our study demonstrates that use of Berberol(®), administered as a single or add-on therapy in statin-intolerant subjects affected by diabetes and hypercholesterolemia is a safe and effective tool capable of improving the patients' lipidic and glycemic profiles | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Berberol® | |
| 650 | 4 | |a berberine | |
| 650 | 4 | |a cholesterol | |
| 650 | 4 | |a ezetimibe | |
| 650 | 4 | |a silymarin | |
| 650 | 4 | |a type 2 diabetes | |
| 700 | 1 | |a Bellone, Iaele |e verfasserin |4 aut | |
| 700 | 1 | |a Rapacioli, Giuliana |e verfasserin |4 aut | |
| 700 | 1 | |a Putignano, Pietro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, metabolic syndrome and obesity : targets and therapy |d 2008 |g 8(2015) vom: 01., Seite 89-96 |w (DE-627)NLM195025180 |x 1178-7007 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2015 |g day:01 |g pages:89-96 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/DMSO.S78877 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2015 |b 01 |h 89-96 | ||